Antibody-drug conjugate · Cytotoxic, directed at AXL receptor tyrosine kinase (AXL) · developed by BioAtla
Phase 2Most advanced trial
1Registered trials
What is Mecbotamab Vedotin?
Mecbotamab vedotin is an antibody-drug conjugate built from a conditionally active antibody against the AXL receptor tyrosine kinase, linked to a cytotoxic agent. The antibody binds AXL-expressing tumor cells preferentially under tumor microenvironment conditions, and after internalization the payload kills the cells. It is being studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
BA-3011
Drug type
Antibody-drug conjugate
Targets
AXL receptor tyrosine kinase (AXL)
Mechanism
Cytotoxic, directed at AXL receptor tyrosine kinase (AXL)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.